Rick Ewing

Rick Ewing is VP, Head of Chemistry at Rapafusyn, a platform company focused on non-degrading molecular glues. Previous to Rapafusyn, Rick held the position of VP, Head of Drug Discovery at the Barer Institute. Prior to Barer, Rick was a senior director in Discovery Chemistry at Bristol Myers Squibb where he led medicinal chemistry teams to deliver 15 development candidates in the therapeutic areas of cardiovascular, diabetes, obesity, and heart failure. Among the development candidates is Milvexian, a first in class Factor XIa inhibitor currently in PIII development. Rick is coinventor on 79 patents, and co-author on 77 publications. In 2023, Rick was awarded the ACS Philadelphia Section Award for distinguished achievement in medicinal chemistry. In 2023, Rick also received the Edison Patent Award in Biotechnology Innovation with colleagues from BMS and Scripps Research. In 2021, he was awarded the ACS Fellow by the American Chemical Society and in 2018 received the Ondetti-Cushman award for leadership of the FXIa drug discovery team. Prior to Bristol Myers Squibb, Rick spent 12 years at RPR (now Sanofi). Rick received his Ph.D. in Organic Chemistry from U. Penn.